AAA
IOVA icon

Affinity Asset Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Affinity Asset Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150,000
Closed -$1.66M – 71
2022
Q2 		$1.66M Buy
+150,000
New +$1.97M 0.7% 35

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Affinity Asset Advisors's IOVA Position: Q3 2024 in Review

Affinity Asset Advisors sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 100 shares — an estimated $802 sold.

Affinity Asset Advisors first reported a position in IOVA in Q4 2020 and held it in 7 quarters. The position peaked at $3.7M in Q3 2021. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Affinity Asset Advisors reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 100 Iovance Biotherapeutics shares in Q3 2024, an estimated $802.
  • Affinity Asset Advisors first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 7 quarters.
  • Affinity Asset Advisors's Iovance Biotherapeutics position peaked at $3.7M in Q3 2021.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.